Sargramostim - Biologic Drug Details

Summary for sargramostim

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for sargramostim

Recent Clinical Trials for sargramostim

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE2
University of Washington	PHASE2
Kuni Foundation	PHASE2

See all sargramostim clinical trials

Pharmacology for sargramostim

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor Granulocyte-Macrophage Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for sargramostim Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for sargramostim Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for sargramostim Derived from Patent Text Search

No patents found based on company disclosures

Market Overview and Financial Trajectory of Sargramostim

Last updated: February 13, 2026

Market Size and Growth Drivers

Sargramostim (marketed as Leukine by Peregrine Pharmaceuticals/MSD) is a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). It stimulates the production of white blood cells and supports immune system recovery. Its primary indications include:

• Hematologic malignancies
• Autologous bone marrow transplantation
• Neutropenia management

The global granulocyte colony-stimulating factor (G-CSF and GM-CSF) market was valued at approximately $3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of approximately 6% up to 2027, driven by increasing incidences of cancers, expanding indications, and rising adoption in supportive care.

Market Dynamics

• Competitive landscape: Sargramostim faces competition from G-CSF agents like filgrastim (Neupogen) and pegfilgrastim (Neulasta). G-CSF agents dominate due to broader approvals and frequent use. GM-CSF options are less prevalent but retain niche roles.

• Regulatory environment: While sargramostim has long-standing approval in the U.S. and Europe, recent approvals for novel indications are limited. Regulatory re-evaluation and labeling updates could influence market penetration.

• Manufacturing and supply chain: As a biologic, sargramostim production involves complex biologic processes. Capacity constraints, batch variability, and manufacturing costs affect pricing and availability.

• Pricing and reimbursement: In the U.S., sargramostim’s average wholesale price (AWP) ranges between $3,000 to $4,000 per dose, with reimbursement dependent on institutional and insurance policies. Reimbursement rates fluctuate based on healthcare policy changes and competitive bidding.

Financial Trajectory

Revenues and Market Penetration: Sargramostim’s revenue has been stable but limited, with estimates around $150 million in 2022 globally.

Key Factors Influencing Revenue:

• Patent and Exclusivity: The original patents expired in the 2010s, opening market access to biosimilars and generics. No major biosimilar has yet gained significant market share, partly due to manufacturing complexities and limited demand for niche indications.

• Pipeline and New Indications: Limited pipeline growth has impeded revenue expansion. Ongoing clinical trials focus on supportive cancer treatment, but success is not assured.

• Pricing Trends: Price pressure from biosimilar entries and healthcare cost containment measures may reduce per-unit revenues. However, extension of labeled indications could stabilize income.

Financial Projections (2023-2027):

Year	Revenue Estimate	Key Drivers
2023	$140 million	Market stabilization, biosimilar competition
2024	$135 million	Slight decline due to pricing pressures
2025	$130 million	Pipeline setbacks
2026	$125 million	Marginal growth from new clinical evidence
2027	$120 million	Market maturation, biosimilar penetration

Future Outlook

• Potential Growth Areas: Use in personalized immunotherapy, novel cancer support protocols, and combination regimens offers limited but promising expansion.

• Impact of Biosimilars: Entry of biosimilar GM-CSFs could diminish revenues by 20-30% over the next 3–5 years if they gain regulatory approval and market acceptance.

• Regulatory and Policy Trends: A move toward value-based care and biosimilar uptake supports cost-containment, potentially stabilizing or reducing revenue.

Conclusion

Sargramostim remains a niche biologic with a stable but slowly declining financial profile. Market growth is constrained by patent expirations, biosimilar competition, and limited pipeline expansion. Its role in hematology and supportive oncology care sustains its relevance, though future growth hinges on clinical and regulatory developments.

---

Key Takeaways

• The global market for GM-CSF biologics like sargramostim is approximately $3 billion with moderate growth prospects.
• Revenues for sargramostim hovered around $150 million in 2022; future projections show a gradual decline influenced by biosimilar competition.
• Market dynamics are driven by competition from G-CSF agents, regulatory factors, and manufacturing complexities.
• Pipeline development remains limited, constraining growth opportunities.
• Price pressures and healthcare reforms could further compress margins and revenues.

---

FAQs

1. What are the primary indications for sargramostim?
   It treats neutropenia related to chemotherapy, supports recovery after stem cell transplantation, and manages other hematologic conditions.

2. Who are sargramostim’s main competitors?
   Filgrastim (Neupogen), pegfilgrastim (Neulasta), and biosimilar GM-CSF formulations.

3. How is the biosimilar landscape affecting sargramostim?
   Biosimilars could reduce prices and market share. No significant biosimilar has gained widespread approval yet but poses a future threat.

4. What innovations could expand sargramostim's use?
   Clinical trials combining sargramostim with immunotherapies or new supportive care protocols could create growth opportunities.

5. What is the outlook for sargramostim's revenue in the next five years?
   Revenues are expected to decline gradually, reaching approximately $120 million by 2027, barring major regulatory or clinical breakthroughs.

---

References

[1] Market research reports on G-CSF and GM-CSF market.
[2] Company financial disclosures and patent expiration data.
[3] Clinical trial registries and FDA labeling updates.
[4] Pricing and reimbursement analyses from healthcare economics studies.